A new gene-editing therapy just dropped LDL cholesterol by 69 percent — with a single injection. One shot, permanent effect. Cue the headlines: “Game-changer!” “End of statins!” “Revolution in heart disease!”

Here we go again.

Let’s be clear: I’m not anti-innovation. I’m not against gene therapy. I’m against making the same mistake again and again, just with better marketing and shinier tools.

VERVE-102 is the latest miracle-in-a-vial — a CRISPR base-editing therapy that …

Read more…

Coronary artery disease is still the world’s number-one killer.

That’s despite statins, PCSK9 inhibitors, stents, bypasses, and decades of lifestyle messaging.

We’ve gotten better at managing heart attacks, but we haven’t cured heart disease. Or prevented it. Or even figured out exactly what causes it.

As an internist and lipidologist (in recovery), I spent years chasing cholesterol numbers, especially HDL. I gave talks for Abbott. I pushed niacin like it was salvation. Then …

Read more…

For decades, you were told that whole milk was the devil in a glass. Doctors (including me), dietitians, and public health agencies told you to toss the red cap and grab the blue — skim, 1 percent, or 2 percent milk. Why? Because whole milk had fat. And fat, particularly saturated fat, was supposed to clog your arteries like grease in a kitchen drain.

Except we were wrong.

The fat in whole …

Read more…

In the late 1970s, a Japanese biochemist named Akira Endo discovered a compound from fungus that inhibited HMG-CoA reductase, the enzyme responsible for making cholesterol. It was an academic curiosity at the time. No one knew if lowering cholesterol would prevent heart attacks—it just lowered a number on a lab slip.

That compound eventually became lovastatin, and in 1987, Merck brought it to market with no proof of improved outcomes—only a …

Read more…

The end of my belief came on a fall night in 2011. I was driving to a suburban restaurant to give a paid dinner talk on Niaspan for Abbott Labs. It was a typical night for a physician speaker—slide deck polished, HDL-cholesterol optimism intact. Then the results of the AIM-HIGH trial came over public radio. Niacin, when added to a statin, had no cardiovascular benefit. My world cracked. I never …

Read more…